Within our areas of focus, we build on a deep understanding of biology and unmet patient needs to pursue world-class medicines and solutions for a number of diseases and conditions.
We focus on a core set of therapeutic areas — ones where we've proven our expertise and where we have even greater potential to improve how diseases and conditions are managed. These include oncology, immunology, neuroscience, eye care, aesthetics and other areas of unmet need.
We're building on our deep expertise and legacy in immunology research to explore new disease areas, create a more patient-centric discovery and development process and offer solutions for more diverse patient populations.
We leverage our deep understanding of human biology and cutting-edge research technologies to find new ways to improve the lives of people with cancer. Our scientific discoveries have made a big impact in the treatment of blood cancer, and now we're expanding our knowledge to investigate solid tumors.
Our scientists are relentless in their pursuit of raising the standards of care for neurological diseases and disorders. We are exploring innovative, disease-modifying solutions to address some of the most prevalent and serious disorders, from Parkinson's, Alzheimer's and broader movement disorders to schizophrenia, migraine and stroke.
Our innovative portfolio and pipeline of new discoveries seek to maintain vision and prevent blindness. We are focused on improving the standards of care across multiple disease areas from the front to the back of the eye, from glaucoma to chronic retinal diseases.
We create products and technologies that advance aesthetic medicine. Our aesthetics R&D team seeks to discover and accelerate comprehensive, evidence-based solutions focused on novel indications, improved delivery technologies and enhanced patient outcomes.
Beyond our core areas, our research is also focused on infectious diseases — like Hepatitis C, HIV and COVID-19 — pulmonology, endocrinology, diseases of the gastrointestinal tract and therapeutic neurotoxins. In these areas, a diverse set of scientific expertise is united by one vision — we believe impactful new discoveries for some of these patients are achievable.
The product-specific site Internet site that you have requested is intended for the residents of a particular country or countries, as noted on that site. As a result, the site may contain information on pharmaceuticals that are not approved in other countries or region. If you are a resident of a country other than those to which the site is directed, please return to AbbVie.com or contact your local AbbVie affiliate to obtain the appropriate product information for your country of residence. The Internet site that you have requested may not be optimized to your screen size. Do you wish to continue to this product-specific site?